nedaplatin has been researched along with Epithelial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H; Sheng, WJ; Wu, DL; Zheng, JH | 1 |
| Duan, Z; Hu, P; Yue, Y; Zhou, X | 1 |
2 other study(ies) available for nedaplatin and Epithelial Neoplasms
| Article | Year |
|---|---|
Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Oxazines; Rats; Signal Transduction; STAT3 Transcription Factor; Survivin; Vascular Endothelial Growth Factor A; Xanthenes | 2013 |
A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2012 |